biologics excipients and ingredients market

Growth of Biologics and Biosimilars Will Drive Above-Average Demand for a Range of Ingredients

A surging number of biologic APIs and their growing penetration into multiple therapies create an attractive market segment for pharmaceutical ingredient suppliers but not one without challenges, analyzes Kline’s recently published Biologics: Market Opportunities for Chemicals Suppliers. To learn about key findings from the study, REGISTER for a complimentary webinar, taking place on October 17, 2019.

Currently, more than 350 biologics are commercially presented in the biopharmaceuticals market. Some established biologics, such as Humira and Avastin, maintained their growth of the last decade in 2018, with sales growing by 8.2% and 9.5%, respectively. New drugs such as Opdivo, which was first introduced in 2017, witnessed particularly robust growth in the overall biopharmaceutical market.Continue reading

Kline Confirms that Excipients are on the Rise in a New Era for Biologics and Topicals

Biologics:

The global pharmaceutical industry is facing a surge biologics. In recent years, biologic drugs have enjoyed a better approval rating than traditional drugs, as biologic drugs have been found to treat major chronic and complex diseases with higher safety and efficacy. The global production of biologics is expected to grow at a rate of around 10% annually.Continue reading

Oral Solids Continue to Dominate the Excipients Market

Oral Solids Continue to Dominate the Excipients Market, While the Parenteral Route Accelerates Growth

By definition, excipients are inactive substances that serve as a medium or vehicle for pharmaceutical active drug substances. Over the years, excipients have been increasingly developed to provide important functionalities to pharmaceutical formulations. The global pharmaceutical market is worth more than USD 1.1 trillion as of 2017 and expected to grow more than 4% annually over the next five years. The global market of specialty excipients in the overall pharmaceutical industry is estimated at about USD 6.8 billion in 2017.Continue reading